{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:37:11Z","timestamp":1787315831535,"version":"build-2736575974"},"reference-count":0,"publisher":"Avens Publishing Group","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Parkinsons Dis Alzheimers Dis"],"DOI":"10.13188\/2376-922x.1000025","type":"journal-article","created":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T05:10:41Z","timestamp":1533359441000},"page":"01-08","source":"Crossref","is-referenced-by-count":13,"title":["Therapeutic Advantages of Dual Targeting of PPAR-\u03b4 and PPAR-\u03b3 in an Experimental Model of Sporadic Alzheimer\u2019s Disease"],"prefix":"10.13188","volume":"5","member":"5316","published-online":{"date-parts":[[2018,6,30]]},"container-title":["Journal of Parkinson\u2019s Disease and Alzheimer\u2019s Disease"],"original-title":["Therapeutic Advantages of Dual Targeting of PPAR-\u03b4 and PPAR-\u03b3 in an Experimental Model of Sporadic Alzheimer\u2019s Disease"],"link":[{"URL":"http:\/\/www.avensonline.org\/fulltextarticles\/JPA-2376-922X-05-0025.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T05:10:42Z","timestamp":1533359442000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.avensonline.org\/fulltextarticles\/JPA-2376-922X-05-0025.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,30]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,6,30]]}},"URL":"https:\/\/doi.org\/10.13188\/2376-922x.1000025","relation":{},"ISSN":["2376-922X"],"issn-type":[{"value":"2376-922X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,30]]}}}